Staffan Holmqvist

Staffan Holmqvist

Auto-generated profile, based on publicly available information

Staffan Holmqvist

Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2018 in Nature
Verified
Journal Article
Closed access
PDF file
RVRoser Vento-Tormo
Roser Vento-Tormo
MEMirjana Efremova
Mirjana Efremova
RBRachel A. Botting
Rachel A. Botting
MTMargherita Y. Turco
Margherita Y. Turco
MVMiquel Vento-Tormo
Miquel Vento-Tormo
STSarah A. Teichmann
Sarah A. Teichmann

9 October 2014 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
SHStaffan Holmqvist
Staffan Holmqvist
OCOldriska Chutna
Oldriska Chutna
LBLuc Bousset
Luc Bousset
PAPatrick Aldrin-Kirk
Patrick Aldrin-Kirk
WLWen Li
Wen Li
JLJia-Yi Li
Jia-Yi Li

17 July 2019 in Nature
Verified
Journal Article
Closed access
PDF file
LSLucas Schirmer
Lucas Schirmer
DVDmitry Velmeshev
Dmitry Velmeshev
SHStaffan Holmqvist
Staffan Holmqvist
MKMax Kaufmann
Max Kaufmann
SWSebastian Werneburg
Sebastian Werneburg
DRDavid H. Rowitch
David H. Rowitch

15 August 2019 in Nature
Verified
Journal Article
Closed access
PDF file
MSMichael Segel
Michael Segel
BNBjörn Neumann
Björn Neumann
MHMyfanwy F. E. Hill
Myfanwy F. E. Hill
IWIsabell P. Weber
Isabell P. Weber
CVCarlo Viscomi
Carlo Viscomi
KCKevin J. Chalut
Kevin J. Chalut

16 March 2020 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
OBOmer Ali Bayraktar
Omer Ali Bayraktar
TBTheresa Bartels
Theresa Bartels
SHStaffan Holmqvist
Staffan Holmqvist
VKVitalii Kleshchevnikov
Vitalii Kleshchevnikov
AMAraks Martirosyan
Araks Martirosyan
DRDavid H. Rowitch
David H. Rowitch

31 October 2017 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
JRJinar Rostami
Jinar Rostami
SHStaffan Holmqvist
Staffan Holmqvist
VLVeronica Lindström
Veronica Lindström
JSJessica Sigvardson
Jessica Sigvardson
GWGunilla T Westermark
Gunilla T Westermark
AEAnna Erlandsson
Anna Erlandsson
Many lines of evidence suggest that the Parkinson's disease (PD)-related protein α-synuclein (α-SYN) can propagate from cell to cell in a prion-like manner. However, the cellular mechanisms behind the spreading remain elusive. Here, we show that human astrocytes derived from embryonic stem cells actively transfer aggregated α-SYN to nearby astrocytes via direct contact and tunneling nanotubes (TNTs). Failure in the astrocytes' lysosomal digestion of excess α-SYN oligomers results in α-SYN deposits in the trans-Golgi network followed by endoplasmic reticulum swelling and mitochondrial disturbances. The stressed astrocytes respond by conspicuously sending out TNTs, enabling intercellular transfer of α-SYN to healthy astrocytes, which in return deliver mitochondria, indicating a TNT-mediated rescue mechanism. Using a pharmacological approach to inhibit TNT formation, we abolished the transfer of both α-SYN and mitochondria. Together, our results highlight the role of astrocytes in α-SYN cell-to-cell transfer, identifying possible pathophysiological events in the PD brain that could be of therapeutic relevance.SIGNIFICANCE STATEMENTAstrocytes are the major cell type in the brain, yet their role in Parkinson's disease progression remains elusive. Here, we show that human astrocytes actively transfer aggregated α-synuclein (α-SYN) to healthy astrocytes via direct contact and tunneling nanotubes (TNTs), rather than degrade it. The astrocytes engulf large amounts of oligomeric α-SYN that are subsequently stored in the trans-Golgi network region. The accumulation of α-SYN in the astrocytes affects their lysosomal machinery and induces mitochondrial damage. The stressed astrocytes respond by sending out TNTs, enabling intercellular transfer of α-SYN to healthy astrocytes. Our findings highlight an unexpected role of astrocytes in the propagation of α-SYN pathology via TNTs, revealing astrocytes as a potential target for therapeutic intervention.